key: cord-0765275-mgobg706
authors: Mahmud, Nadim; Weiss, Alexandra; Trivedi, Chinmay; Yang, Yu-Xiao; Lewis, James; Khan, Nabeel
title: Risk of Venous Thromboembolism among Inflammatory Bowel Disease patients who contract SARS-CoV-2
date: 2021-06-15
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.06.012
sha: d726c40e3757ddc4591b53ac804b5d5477c4f7f2
doc_id: 765275
cord_uid: mgobg706

nan

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic affecting over 166 million people worldwide. (1) Inflammatory bowel disease (IBD) is a common disorder affecting more than 6.8 million people globally, (2) and the association between IBD and the development of venous thromboembolism (VTE) has been well described. (3) The association between COVID-19 disease and VTE has also been described, (4) however to date there are no published data addressing the incremental risk of VTE in patients with underlying IBD who contract SARS-CoV-2. To evaluate this, we studied a nationwide cohort of IBD patients in the Veterans Affairs (VA) healthcare system.

See Supplement for extended methods. This was a case crossover study of patients with IBD and VTE in an established VA cohort. The case crossover design only uses data from patients with the outcome of interest and compares the prevalence of exposure immediately prior to the outcome to other times, such that each patient is compared to themselves at other times. We identified all patients with IBD prior to March 1st, 2020 (index date) who were actively followed in the VA and who developed an incident VTE event between April 1 st , 2020 and March 30 th , 2021. Demographics, IBD medication, corticosteroid use, anticoagulation medication, and comorbidity data were obtained for each patient, in addition to dates of SARS-CoV-2 infection (via polymerase chain reaction). Descriptive statistics were reported as medians and interquartile ranges (IQRs) for continuous variables and as percentages for categorical variables. For the primary analysis, we established a 30-day window prior to VTE for each patient (case period), and subsequently generated ten 30-day window control periods (non-overlapping with the case period, also between April 1 st , 2020 and March 30 th , 2021) for each patient using a random number generator. Control periods could occur before or after case periods, as the outcome of thrombosis was not thought to impact future risk of SARS-CoV-2 infection, and it was important to include periods throughout the study duration given a fluctuating national burden of COVID-19. For each case and control window, the presence or absence of SARS-CoV-2 infection was designated as the exposure.

Conditional logistic regression using a 1:10 case:control ratio was used to estimate the odds ratio and 95% confidence interval (CI) for the association of VTE with SARS-CoV-2 infection, adjusting for all-cause hospitalization at the start of the 30-day window and time-updated corticosteroid use in the prior 30 days.

Stratified analyses were performed based on usage of chronic anticoagulation medications prior to VTE. However, the association was stronger among patients not previously on anticoagulation (OR 14.31, 95% CI 6.90-29.66, p<0.001).

In this nationwide cohort, we identified a significant positive association between SARS-CoV-2 infection and VTE events in patients with IBD. Prior studies demonstrate 2-3-fold increased odds of developing VTE in patients with IBD compared to the general population, in both hospitalized and ambulatory settings. (5, 6) The pathogenesis of VTE in IBD is multifactorial and findings suggest that there is not one particular mechanism that leads to hypercoagulability in IBD, but rather a complex interplay of systems. The mechanisms of hemostatic imbalance in SARS-CoV-2 infection are similarly complex. In patients with infections such as COVID-19, endothelial dysfunction caused by the infectious process increases thrombin production and terminates fibrinolysis, which in turn promotes a hypercoagulable state. increased VTE risk. Importantly, the identified association between SARS-CoV-2 and VTE in the IBD cohort was entirely mitigated among patients who were on anti-coagulation therapy when they contracted SARS-CoV-2. This suggests that there may be a possible role for VTE pharmaco-prophylaxis especially among high-risk IBD patients who contract SARS-CoV-2.

Major strengths of our study include the use of a nationwide study cohort with a geographically diverse patient population, and a self-controlled study design. The VA has devised a system in which all positive SARS-CoV-2 cases are recorded even if they are diagnosed outside the VA. The pharmacy dataset is very comprehensive, and veterans are likely to get their medications filled in the VA as there is little or no co-pay. Limitations include the retrospective nature of the study. We may also have missed thrombotic episodes diagnosed outside the VA J o u r n a l P r e -p r o o f system, but we suspect the numbers would be low as we only included patients who were actively followed in the VA.

To the best of our knowledge, this study is the first to detail the strength of association between SARS-CoV-2 and subsequent VTE in patients with underlying IBD. Our data suggest that IBD patients who contract SARS-CoV-2 have a substantially increased risk of VTE and may therefore benefit from prophylaxis. 

The Lancet gastroenterology & hepatology

Alimentary pharmacology & therapeutics

The Lancet

Thrombosis research